- Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT2021 | First Faculty of Medicine
- Treatment of older patients with mantle-cell lymphoma2012 | First Faculty of Medicine
- Use of ibrutinib as "bridging" for allogeneic hematopoietic stem cell transplantation from haploidentic donor and subsequent therapy of residual disease after transplantation in a patient with highly adverse mantle cell lymphoma2019 | First Faculty of Medicine
- Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study2019 | Faculty of Medicine in Hradec Králové
- Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial2016 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data2021 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation2019 | First Faculty of Medicine, Third Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial2019 | First Faculty of Medicine
- Characteristics and results of treatment of younger patients less than 60 years old with AML: analysis of real data from the Czech DATOOL-AML database2020 | Third Faculty of Medicine, Central Library of Charles University
- A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel2022 | First Faculty of Medicine, Faculty of Science
- Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial2020 | First Faculty of Medicine
- 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis2020 | First Faculty of Medicine
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial2019 | Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial2017 | Second Faculty of Medicine
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial2023 | Publication without faculty affiliation
- Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study2020 | Faculty of Medicine in Hradec Králové